Figure 4
Mobilization of MM1S Heca452-enriched cells from BM to PB following GMI-1271 treatment. Seven-week-old female scid mice were injected i.v. with 5 × 106 MM1s Heca452 variant myeloma cells and 30 days post tumor injection were treated i.p. with a single injection of saline, 40 mg/kg GMI-1271 or 5 mg/kg AMD-3100. Peripheral blood was collected by intracardiac puncture at 1, 2, 4 and 24 h post injection of saline or GMI-1271 (n=3 mice per time point) and at 4 and 24 h post injection of AMD-3100. The number of MM1s Heca452 myeloma cells was determined by flow cytometry using an anti-human CD138 antibody. Bars represent s.d. The two tailed t-test was used to determine statistical significance between GMI-1271 and AMD-3100, and between GMI-1271 and saline at 4 and 24 h. ** and *** represent P-values <0.01 and 0.001, respectively. i.v., intravenously; n.s, non significant.
